Antibiotic resistance in invasive Streptococcus pneumoniae isolates identified in Scotland between 1999 and 2007

Benjamin Cooke, Andrew Smith, Mathew Diggle, Karen Elaine Lamb, Christopher Robertson, Donald Inverarity, Johanna Jefferies, Giles Edwards, Timothy Mitchell, Stuart Clarke, Jim McMenamin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Data from 4,727 invasive isolates of Streptococcus pneumoniae, submitted to the Scottish Haemophilus, Legionella, Meningococcus and Pneumococcus Reference Laboratory between 1999 and 2007, were analysed to establish susceptibility profiles to penicillin, erythromycin and cefotaxime. Pneumococcal resistance to penicillin over the study period remained low, with only 0.2%, (n= 7/4,727), isolates falling into this category, (MIC great than or equal to 2 mg/l). These isolates have been sporadic, and have mainly represented serogroup 14 (ST9) and 9 (ST156). In comparison, the 'intermediate sensitivity' group, (MIC 0.12-1 mg l-1), ranged between 2-6% per year, the majority from serogroup 9 (ST156). Over the study period we found 12%, (n= 585/4,727), of isolates were erythromycin resistant, (MIC >0.5 mg l1), with the majority, (n= 467; 80%), of these isolates identified as serogroup 14 (ST9). Cephalosporin resistance, (cefotaxime MIC >1mg l-1), was found in only 0.06%, (n= 2/3,135), of isolates. Internationally recognised clones, (Pneumococcal Molecular Epidemiology Network, PMEN), accounted for 35%, (n=28/81), of the penicillin-non-susceptible isolates, and 75%, (n=248/330), of the macrolide-resistant isolates, with ST9 and ST 306 predominating. Between 1999 and 2007 we found that 11.6%, (n=18/155), of the penicillin non-susceptible isolates and 4.8%, (n=28/585), of the macrolide-resistant isolates were from serogroups not covered by the 7-valent conjugate pneumococcal vaccine in use in the UK since 2006. Susceptibility to first line antimicrobial agents for invasive pneumococcal disease, (IPD), in Scotland has remained high over the period 1999-2007.




LanguageEnglish
Pages1212-1218
Number of pages7
JournalJournal of Medical Microbiology
Volume59
DOIs
Publication statusPublished - 22 Jul 2010

Fingerprint

Scotland
Microbial Drug Resistance
Streptococcus pneumoniae
Penicillins
Cefotaxime
Macrolides
Erythromycin
Cephalosporin Resistance
Haemophilus
Penicillin Resistance
Legionella
Conjugate Vaccines
Pneumococcal Vaccines
Neisseria meningitidis
Molecular Epidemiology
Anti-Infective Agents
Clone Cells
Serogroup

Keywords

  • streptococcus pneumoniae
  • medical microbiology

Cite this

Cooke, Benjamin ; Smith, Andrew ; Diggle, Mathew ; Lamb, Karen Elaine ; Robertson, Christopher ; Inverarity, Donald ; Jefferies, Johanna ; Edwards, Giles ; Mitchell, Timothy ; Clarke, Stuart ; McMenamin, Jim. / Antibiotic resistance in invasive Streptococcus pneumoniae isolates identified in Scotland between 1999 and 2007. In: Journal of Medical Microbiology. 2010 ; Vol. 59. pp. 1212-1218.
@article{e92e05bf5ee24f47b9df526d55f81631,
title = "Antibiotic resistance in invasive Streptococcus pneumoniae isolates identified in Scotland between 1999 and 2007",
abstract = "Data from 4,727 invasive isolates of Streptococcus pneumoniae, submitted to the Scottish Haemophilus, Legionella, Meningococcus and Pneumococcus Reference Laboratory between 1999 and 2007, were analysed to establish susceptibility profiles to penicillin, erythromycin and cefotaxime. Pneumococcal resistance to penicillin over the study period remained low, with only 0.2{\%}, (n= 7/4,727), isolates falling into this category, (MIC great than or equal to 2 mg/l). These isolates have been sporadic, and have mainly represented serogroup 14 (ST9) and 9 (ST156). In comparison, the 'intermediate sensitivity' group, (MIC 0.12-1 mg l-1), ranged between 2-6{\%} per year, the majority from serogroup 9 (ST156). Over the study period we found 12{\%}, (n= 585/4,727), of isolates were erythromycin resistant, (MIC >0.5 mg l1), with the majority, (n= 467; 80{\%}), of these isolates identified as serogroup 14 (ST9). Cephalosporin resistance, (cefotaxime MIC >1mg l-1), was found in only 0.06{\%}, (n= 2/3,135), of isolates. Internationally recognised clones, (Pneumococcal Molecular Epidemiology Network, PMEN), accounted for 35{\%}, (n=28/81), of the penicillin-non-susceptible isolates, and 75{\%}, (n=248/330), of the macrolide-resistant isolates, with ST9 and ST 306 predominating. Between 1999 and 2007 we found that 11.6{\%}, (n=18/155), of the penicillin non-susceptible isolates and 4.8{\%}, (n=28/585), of the macrolide-resistant isolates were from serogroups not covered by the 7-valent conjugate pneumococcal vaccine in use in the UK since 2006. Susceptibility to first line antimicrobial agents for invasive pneumococcal disease, (IPD), in Scotland has remained high over the period 1999-2007.",
keywords = "streptococcus pneumoniae , medical microbiology",
author = "Benjamin Cooke and Andrew Smith and Mathew Diggle and Lamb, {Karen Elaine} and Christopher Robertson and Donald Inverarity and Johanna Jefferies and Giles Edwards and Timothy Mitchell and Stuart Clarke and Jim McMenamin",
year = "2010",
month = "7",
day = "22",
doi = "10.1099/jmm.0.022954-0",
language = "English",
volume = "59",
pages = "1212--1218",
journal = "Journal of medical microbiology",
issn = "0022-2615",

}

Cooke, B, Smith, A, Diggle, M, Lamb, KE, Robertson, C, Inverarity, D, Jefferies, J, Edwards, G, Mitchell, T, Clarke, S & McMenamin, J 2010, 'Antibiotic resistance in invasive Streptococcus pneumoniae isolates identified in Scotland between 1999 and 2007' Journal of Medical Microbiology, vol. 59, pp. 1212-1218. https://doi.org/10.1099/jmm.0.022954-0

Antibiotic resistance in invasive Streptococcus pneumoniae isolates identified in Scotland between 1999 and 2007. / Cooke, Benjamin; Smith, Andrew; Diggle, Mathew; Lamb, Karen Elaine; Robertson, Christopher; Inverarity, Donald; Jefferies, Johanna; Edwards, Giles; Mitchell, Timothy; Clarke, Stuart; McMenamin, Jim.

In: Journal of Medical Microbiology, Vol. 59, 22.07.2010, p. 1212-1218.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antibiotic resistance in invasive Streptococcus pneumoniae isolates identified in Scotland between 1999 and 2007

AU - Cooke, Benjamin

AU - Smith, Andrew

AU - Diggle, Mathew

AU - Lamb, Karen Elaine

AU - Robertson, Christopher

AU - Inverarity, Donald

AU - Jefferies, Johanna

AU - Edwards, Giles

AU - Mitchell, Timothy

AU - Clarke, Stuart

AU - McMenamin, Jim

PY - 2010/7/22

Y1 - 2010/7/22

N2 - Data from 4,727 invasive isolates of Streptococcus pneumoniae, submitted to the Scottish Haemophilus, Legionella, Meningococcus and Pneumococcus Reference Laboratory between 1999 and 2007, were analysed to establish susceptibility profiles to penicillin, erythromycin and cefotaxime. Pneumococcal resistance to penicillin over the study period remained low, with only 0.2%, (n= 7/4,727), isolates falling into this category, (MIC great than or equal to 2 mg/l). These isolates have been sporadic, and have mainly represented serogroup 14 (ST9) and 9 (ST156). In comparison, the 'intermediate sensitivity' group, (MIC 0.12-1 mg l-1), ranged between 2-6% per year, the majority from serogroup 9 (ST156). Over the study period we found 12%, (n= 585/4,727), of isolates were erythromycin resistant, (MIC >0.5 mg l1), with the majority, (n= 467; 80%), of these isolates identified as serogroup 14 (ST9). Cephalosporin resistance, (cefotaxime MIC >1mg l-1), was found in only 0.06%, (n= 2/3,135), of isolates. Internationally recognised clones, (Pneumococcal Molecular Epidemiology Network, PMEN), accounted for 35%, (n=28/81), of the penicillin-non-susceptible isolates, and 75%, (n=248/330), of the macrolide-resistant isolates, with ST9 and ST 306 predominating. Between 1999 and 2007 we found that 11.6%, (n=18/155), of the penicillin non-susceptible isolates and 4.8%, (n=28/585), of the macrolide-resistant isolates were from serogroups not covered by the 7-valent conjugate pneumococcal vaccine in use in the UK since 2006. Susceptibility to first line antimicrobial agents for invasive pneumococcal disease, (IPD), in Scotland has remained high over the period 1999-2007.

AB - Data from 4,727 invasive isolates of Streptococcus pneumoniae, submitted to the Scottish Haemophilus, Legionella, Meningococcus and Pneumococcus Reference Laboratory between 1999 and 2007, were analysed to establish susceptibility profiles to penicillin, erythromycin and cefotaxime. Pneumococcal resistance to penicillin over the study period remained low, with only 0.2%, (n= 7/4,727), isolates falling into this category, (MIC great than or equal to 2 mg/l). These isolates have been sporadic, and have mainly represented serogroup 14 (ST9) and 9 (ST156). In comparison, the 'intermediate sensitivity' group, (MIC 0.12-1 mg l-1), ranged between 2-6% per year, the majority from serogroup 9 (ST156). Over the study period we found 12%, (n= 585/4,727), of isolates were erythromycin resistant, (MIC >0.5 mg l1), with the majority, (n= 467; 80%), of these isolates identified as serogroup 14 (ST9). Cephalosporin resistance, (cefotaxime MIC >1mg l-1), was found in only 0.06%, (n= 2/3,135), of isolates. Internationally recognised clones, (Pneumococcal Molecular Epidemiology Network, PMEN), accounted for 35%, (n=28/81), of the penicillin-non-susceptible isolates, and 75%, (n=248/330), of the macrolide-resistant isolates, with ST9 and ST 306 predominating. Between 1999 and 2007 we found that 11.6%, (n=18/155), of the penicillin non-susceptible isolates and 4.8%, (n=28/585), of the macrolide-resistant isolates were from serogroups not covered by the 7-valent conjugate pneumococcal vaccine in use in the UK since 2006. Susceptibility to first line antimicrobial agents for invasive pneumococcal disease, (IPD), in Scotland has remained high over the period 1999-2007.

KW - streptococcus pneumoniae

KW - medical microbiology

UR - http://www.scopus.com/inward/record.url?scp=77957291672&partnerID=8YFLogxK

U2 - 10.1099/jmm.0.022954-0

DO - 10.1099/jmm.0.022954-0

M3 - Article

VL - 59

SP - 1212

EP - 1218

JO - Journal of medical microbiology

T2 - Journal of medical microbiology

JF - Journal of medical microbiology

SN - 0022-2615

ER -